Selecting appropriate management strategies for chronic hepatitis B: Who to treat

American Journal of Gastroenterology

Volumn 101, Issue 1 SUPPL. 1, 2006, Pages

  McMahon, Brian J ^a  

^a ALASKA NATIVE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA2A; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; ENTERITIS; FOLLOW UP; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; MEDICAL LITERATURE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK FACTOR; SCREENING;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; MASS SCREENING; PRACTICE GUIDELINES; WORLD HEALTH;

EID: 33644886882     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00446.x     Document Type: Review

References (27)

1. Lee W Hepatitis B virus infection N Engl J Med 1997 337 1733 45
2. Beasley RP Hepatitis B virus: The major etiology of hepatocellular carcinoma Cancer 1988 61 1942 56
3. McMahon BJ Hepatocellular carcinoma and viral hepatitis In Wilson RA ed Viral hepatitis New York Marcel Dekker 1997 315 30
4. McMahon BJ Holck P Bulkow L et al Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus Ann Intern Med 2001 135 759 68
5. McQuillan GM Townsend TR Fields HA et al Seroepidemiology of hepatitis B virus infection in the United States Am J Med 1989 87 suppl 3A 5S 10S
6. Lok ASF McMahon BJ American Association for the Study of Liver Disease Practice Guideline: Chronic hepatitis B: Update of recommendations Hepatology 2004 39 1 5
7. McMahon BJ The natural history of chronic hepatitis B virus infection Semin Liver Dis 2004 24 suppl 1 17 22
8. Hepatitis B virus: A comprehensive strategy for limiting transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP) MMWR Recomm Rep 1991 40 RR-13 1 25
9. Lok AS Heathcote EJ Hoofnagle JH Management of hepatitis B 2000, summary of a workshop Gastroenterology 2001 120 1828 53
10. Lok ASK Lai CL Acute exacerbations in Chinese patients with chronic hepatitis B (HBV) virus infection: Incidence, predisposing factors and etiology J Hepatol 1990 10 29 34
11. Chu CJ Keeffe EB Han SY et al Hepatitis B virus genotypes in the United States: Results of a nationwide study Gastroenterology 2003 125 444 51
12. Chu CJ Keeffe EB Han SY et al Prevalence of HBV precore/core promoter variants in the United States Hepatology 2003 38 619 28
13. Hadziyannis SJ Hepatitis D Clin Liver Dis 1999 3 309 25
14. Housset C Pol S Carnot F et al Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus Hepatology 1992 15 578 92
15. Chung HT Lai CL Wu PC et al Synergism of chronic alcoholism and hepatitis B infection in liver disease J Gastroenterol Hepatol 1989 4 11 6
16. Castera L Hezode C Roudot-Thoraval F et al Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies Gut 2003 52 288 92
17. The EASL Jury EASL International Consensus Conference on Hepatitis B 13-14 September, 2002, Geneva, Switzerland. Consensus statement (short version) J Hepatol 2003 38 533 40
18. Liaw YF Leung N Guan R et al Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update Liver Internat 2005 25 472 89
19. Yeo W Chan PKS Zhong S et al Frequency of hepatitis virus reactivation in cancer patients undergoing cytotoxic chemotherapy. A prospective study of 626 patients with identification of risk factors J Med Virol 2000 62 299 307
20. Yeo W Chan PKS Ho WH et al Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy J Clin Oncol 2004 22 927 34
21. Xunrong L Yan AW Liang R et al Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy - Pathogenesis and management Rev Med Virol 2001 11 287 99
22. Esteve M Saro C Gonzalez-Huix F et al Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: Need for primary prophylaxis Gut 2004 53 1363 5
23. Di Bisceglie AM Waggoner JG Hoofnagle JH Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers: Correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy Gastroenterology 1987 93 1236 41
24. Manesis EK Papatheodoridis GV Sevastianos V et al Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection J Gastroenterol 2003 98 2261 7
25. Chu CJ Hussain M Lok ASF Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection Hepatology 2002 36 1408 15
26. Yuen MF Ng OLN Fan ST et al Significance of HBV DNA levels in liver histology of HBeAg and anti-HBe-positive patients with chronic hepatitis B Am J Gastroenterol 2004 99 2030 7
27. Keeffe EB Dieterich DT Han SHB et al A treatment algorithm for the management of chronic hepatitis B virus infection in the United States Clin Gastroenterol Hepatol 2004 2 87 106